JOP20210130A1 - مثبطات apol1 وطرق استخدامها - Google Patents

مثبطات apol1 وطرق استخدامها

Info

Publication number
JOP20210130A1
JOP20210130A1 JOP/2021/0130A JOP20210130A JOP20210130A1 JO P20210130 A1 JOP20210130 A1 JO P20210130A1 JO P20210130 A JOP20210130 A JO P20210130A JO P20210130 A1 JOP20210130 A1 JO P20210130A1
Authority
JO
Jordan
Prior art keywords
same
methods
apol1
inhibitors
ndkd
Prior art date
Application number
JOP/2021/0130A
Other languages
English (en)
Inventor
Yi Shi
Ales Medek
Michael Brodney
Leslie A Dakin
Warren A Dorsch
Francois Denis
Peter Rose
Timothy J Senter
Muna Shrestha
Camil Sayegh
Kevin Gagnon
Anne Fortier
Jingrong Cao
Elaine B Krueger
Jon H Come
Brian Ledford
Suganthini S Nanthakumar
Olivier Nicolas
Martine Hamel
Kan-Nian Hu
Tiansheng Wang
Faith Witkos
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of JOP20210130A1 publication Critical patent/JOP20210130A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0816—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring comprising Si as a ring atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/46—Phosphinous acids [R2POH], [R2P(= O)H]: Thiophosphinous acids including[R2PSH]; [R2P(=S)H]; Aminophosphines [R2PNH2]; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

غير متوفر
JOP/2021/0130A 2018-12-17 2019-12-17 مثبطات apol1 وطرق استخدامها JOP20210130A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862780667P 2018-12-17 2018-12-17
PCT/US2019/066746 WO2020131807A1 (en) 2018-12-17 2019-12-17 Inhibitors of apol1 and methods of using same

Publications (1)

Publication Number Publication Date
JOP20210130A1 true JOP20210130A1 (ar) 2023-01-30

Family

ID=69182627

Family Applications (3)

Application Number Title Priority Date Filing Date
JOP/2021/0129A JOP20210129A1 (ar) 2018-12-17 2019-12-17 مثبطات apol1 وطرق استخدامها
JOP/2021/0130A JOP20210130A1 (ar) 2018-12-17 2019-12-17 مثبطات apol1 وطرق استخدامها
JOP/2021/0131A JOP20210131A1 (ar) 2018-12-17 2019-12-17 مثبطات apol1 وطرق استخدامها

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JOP/2021/0129A JOP20210129A1 (ar) 2018-12-17 2019-12-17 مثبطات apol1 وطرق استخدامها

Family Applications After (1)

Application Number Title Priority Date Filing Date
JOP/2021/0131A JOP20210131A1 (ar) 2018-12-17 2019-12-17 مثبطات apol1 وطرق استخدامها

Country Status (23)

Country Link
US (2) US11618746B2 (ar)
EP (1) EP3897833A1 (ar)
JP (1) JP2022515369A (ar)
KR (1) KR20210116483A (ar)
CN (1) CN113453760B (ar)
AR (1) AR116913A1 (ar)
AU (1) AU2019405477A1 (ar)
BR (1) BR112021011564A2 (ar)
CA (1) CA3121910A1 (ar)
CL (1) CL2021001561A1 (ar)
CO (1) CO2021009053A2 (ar)
CR (1) CR20210383A (ar)
DO (1) DOP2021000116A (ar)
EC (1) ECSP21052184A (ar)
IL (1) IL283592A (ar)
JO (3) JOP20210129A1 (ar)
MA (1) MA54538A (ar)
MX (1) MX2021007152A (ar)
PE (1) PE20212302A1 (ar)
SG (1) SG11202105769XA (ar)
TW (1) TW202039471A (ar)
UY (1) UY38514A (ar)
WO (1) WO2020131807A1 (ar)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019405477A1 (en) 2018-12-17 2021-06-24 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
AU2021213758A1 (en) * 2020-01-29 2022-09-01 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
WO2021158666A1 (en) * 2020-02-04 2021-08-12 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and methods of using same
CA3173808A1 (en) * 2020-03-06 2021-09-10 Vertex Pharmaceuticals Incorporated Methods of treating apol-1 dependent focal segmental glomerulosclerosis
AU2021333776A1 (en) * 2020-08-26 2023-03-16 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
US20230119114A1 (en) * 2021-08-26 2023-04-20 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitors and methods of using same
CA3240523A1 (en) * 2021-11-30 2023-06-08 Vertex Pharmaceuticals Incorporated Spirocyclic inhibitors of apol1 and methods of using same
WO2023141432A2 (en) 2022-01-18 2023-07-27 Maze Therapeutics, Inc. Apol1 inhibitors and methods of use
WO2023154344A1 (en) * 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated 2-methyl-4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same
WO2023194895A1 (en) 2022-04-06 2023-10-12 Glaxosmithkline Intellectual Property Development Limited Pyrrol derivatives as inhibitors of apolipoprotein l-1
WO2024040235A1 (en) * 2022-08-19 2024-02-22 Maze Therapeutics, Inc. Apol1 inhibitors and methods of use

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2801585B1 (fr) 1999-11-25 2002-02-15 Fournier Ind & Sante Nouveaux antagonistes des recepteurs de l'ii-8
AU2002211828A1 (en) 2000-10-02 2002-04-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
FR2824826B1 (fr) 2001-05-17 2003-11-07 Fournier Lab Sa Nouveaux derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8
FR2824827B1 (fr) 2001-05-17 2004-02-13 Fournier Lab Sa Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8
EP1458693A4 (en) 2001-11-14 2005-02-09 Teva Pharma Amorphous and crystalline forms of losartan potassium and method for making same
AU2003237593A1 (en) * 2002-06-05 2003-12-22 Natco Pharma Limited Process for the preparation of 4-(4-fluorobenzoyl) butyric acid
US8053440B2 (en) * 2007-02-01 2011-11-08 Resverlogix Corporation Compounds for the prevention and treatment of cardiovascular diseases
JP5517935B2 (ja) 2007-08-17 2014-06-11 エルジー・ライフ・サイエンシーズ・リミテッド 細胞壊死阻害剤としてのインドール及びインダゾール化合物
KR101605061B1 (ko) 2009-05-29 2016-03-21 라퀄리아 파마 인코포레이티드 칼슘 또는 나트륨 채널 차단제로서의 아릴 치환된 카복사미드 유도체
WO2014085154A1 (en) 2012-11-27 2014-06-05 Beth Israel Deaconess Medical Center, Inc. Methods for treating renal disease
US9850203B2 (en) 2013-09-26 2017-12-26 Pharmakea, Inc. Autotaxin inhibitor compounds
CA2959437C (en) 2014-08-27 2018-03-06 The Governing Council Of The University Of Toronto Cannabinoid type 1 receptor modulators
US10654838B2 (en) 2014-10-08 2020-05-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Aminopyridine compounds useful as inhibitors of protein prenylation
RS61719B1 (sr) 2015-08-27 2021-05-31 Pfizer Biciklična fuzionisana hetaroaril ili aril jedinjenja kao modulatori irak4
AU2019405477A1 (en) 2018-12-17 2021-06-24 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
AU2021213758A1 (en) 2020-01-29 2022-09-01 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
WO2021158666A1 (en) 2020-02-04 2021-08-12 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and methods of using same
CA3173808A1 (en) * 2020-03-06 2021-09-10 Vertex Pharmaceuticals Incorporated Methods of treating apol-1 dependent focal segmental glomerulosclerosis
AU2021286728A1 (en) 2020-06-12 2023-01-19 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and use of the same
CN115867532A (zh) 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1的抑制剂及其用途
MX2022015766A (es) 2020-06-12 2023-02-23 Vertex Pharma Formas sólidas del inhibidor de apol1 y uso de las mismas.
AU2021333776A1 (en) 2020-08-26 2023-03-16 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same

Also Published As

Publication number Publication date
JP2022515369A (ja) 2022-02-18
IL283592A (en) 2021-07-29
US20230271945A1 (en) 2023-08-31
TW202039471A (zh) 2020-11-01
SG11202105769XA (en) 2021-07-29
UY38514A (es) 2020-07-31
DOP2021000116A (es) 2021-09-30
CO2021009053A2 (es) 2021-08-09
CL2021001561A1 (es) 2021-11-26
AU2019405477A1 (en) 2021-06-24
US11618746B2 (en) 2023-04-04
MX2021007152A (es) 2021-11-03
CN113453760B (zh) 2024-05-24
US20200377479A1 (en) 2020-12-03
ECSP21052184A (es) 2021-08-31
PE20212302A1 (es) 2021-12-10
AR116913A1 (es) 2021-06-23
CR20210383A (es) 2021-09-22
CA3121910A1 (en) 2020-06-25
BR112021011564A2 (pt) 2021-08-31
WO2020131807A1 (en) 2020-06-25
KR20210116483A (ko) 2021-09-27
JOP20210129A1 (ar) 2023-01-30
CN113453760A (zh) 2021-09-28
MA54538A (fr) 2021-10-27
JOP20210131A1 (ar) 2023-01-30
EP3897833A1 (en) 2021-10-27

Similar Documents

Publication Publication Date Title
CR20210383A (es) Inhibidores de apol 1 y sus métodos de uso
CR20200347A (es) Inhibidores pd-1/pd-l1
CR20200520A (es) Compuestos heterocíclicos como inmunomoduladores
CO2021005884A2 (es) Moduladores de la alfa-1 antitripsina
MX2020009115A (es) Inhibidores de cd73.
EA202191082A1 (ru) Соединения пиридазинонов и их применения
GEP20227443B (en) Magl inhibitors
EA202191084A1 (ru) Соединения пиридазинонов и их применения
MX2015011097A (es) Inhibidores de histona desmetilasas.
EA202092086A1 (ru) Ингибиторы аргиназы
EA202090497A1 (ru) Соединения и композиции для лечения гематологических нарушений
MX2021003187A (es) Inhibición de la peptidasa específica de ubiquitina 9x.
MX2023002269A (es) Inhibidores de apol1 y metodos para usar los mismos.
MX2022007841A (es) Degradadores del regulador dependiente de actina asociado a la matriz relacionado con el complejo switch/sacarosa no fermentable de la subfamilia a de la cromatina (smarca)y usos de los mismos.
MX2020012281A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
EA202092748A1 (ru) Модуляторы экспрессии apol1
PH12021551365A1 (en) Compositions and methods for treating and preventing amyotrophic lateral sclerosis
EA202090424A1 (ru) Бициклические ингибиторы гистондеацетилазы
WO2018189661A3 (en) Methods and compounds for treating diabetes
ZA202106519B (en) Caspase inhibitors and methods of use thereof
EA201892376A1 (ru) Комбинированный состав трех противовирусных соединений
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
WO2020102243A3 (en) In-flow photooxygenation of aminothienopyridinones generates novel ptp4a3 phosphatase inhibitors
WO2018183219A3 (en) Nucleic acid-based compositions and methods for treating small vessel diseases
EP4293036A3 (en) Structure of gii.4 norovirus protease -design of broad-spectrum protease inhibitors